Sildenafil for Pulmonary Hypertension: How It Works and How It Is Prescribed

Sildenafil is licensed in the UK to treat pulmonary arterial hypertension in adults and in children aged 1 to 17. It relaxes the blood vessels of the lungs, reducing the resistance the right side of the heart has to pump against. The pulmonary product is a different product from the erectile dysfunction tablets, at a different strength and on a different dosing pattern, prescribed only through specialist services.

Two things need saying at the top, because this page is read by two very different groups.

If you or someone you care for is being treated for pulmonary arterial hypertension, this page explains what the medicine does, how it is prescribed and what is monitored. It is background to help you follow a conversation with your specialist team, not a substitute for that team.

If you are wondering whether erectile dysfunction sildenafil could be used for pulmonary hypertension, the answer is no, and the reasons are set out in full below.

Key things to know

• Sildenafil is licensed for pulmonary arterial hypertension in adults and in children aged 1 to 17
• It works as a vasodilator, relaxing blood vessels by preventing the breakdown of a messenger called cGMP
• The pulmonary product is separate from the erectile dysfunction tablets, at a different strength, taken regularly through the day rather than as needed
• Treatment is initiated and supervised by specialist services. It is not a private online prescription route
• Sildenafil is contraindicated with nitrates or nitric oxide donors, and must not be used with riociguat, because the combination can cause a clinically significant fall in blood pressure
• Medicines affecting the CYP3A4 enzyme can change sildenafil levels, so the specialist team reviews everything you take before and during treatment
• It should be used with particular caution if pulmonary veno-occlusive disease is suspected, because pulmonary vasodilators may worsen the patient's cardiovascular condition
• A trial of sildenafil in pregnancy was stopped early after excess cases of persistent pulmonary hypertension of the newborn and excess deaths
• No life expectancy figure appears in the reviewed product information
• Treatment suitability depends on an individual clinical assessment

What Sildenafil Does in Pulmonary Hypertension

How It Helps

Pulmonary arterial hypertension, usually shortened to PAH, raises blood pressure in the arteries carrying blood from the heart to the lungs. Those arteries narrow and stiffen, so the right side of the heart has to work harder to push blood through them. Over time that strain is the central problem.

Sildenafil causes relaxation of pulmonary vascular smooth muscle, helping to reduce pulmonary vascular resistance. It is a potent and selective inhibitor of the enzyme that breaks down cyclic guanosine monophosphate, usually shortened to cGMP. When cGMP is not being broken down as fast, levels rise, and higher cGMP relaxes the smooth muscle in blood vessel walls.

Relaxed vessels are wider vessels. Wider vessels offer less resistance. Less resistance means the right side of the heart has an easier job.

What the Licence Actually Covers

The licensed indication is pulmonary arterial hypertension specifically, in adults and in children aged 1 to 17.

That word arterial matters more than people expect. Pulmonary hypertension is a broad description covering raised pressure in the lung circulation from many causes, including lung disease and left-sided heart disease. Pulmonary arterial hypertension is one particular group within that, and it is the group the licence covers.

So saying sildenafil treats pulmonary hypertension is a loose statement. Saying it is licensed for pulmonary arterial hypertension is the accurate one, and establishing which group a person falls into is exactly what a specialist assessment does before treatment begins.

The pulmonary arterial hypertension product is marketed under its own brand name, separate from the erectile dysfunction brands, and generic versions exist.

How It Is Prescribed

The Prescription Route

Treatment for pulmonary arterial hypertension is initiated and supervised through specialist services, not through a general prescription or a private online consultation.

The reasons are specific to the condition rather than bureaucratic:

• Diagnosis requires specialist investigation. Establishing that someone has pulmonary arterial hypertension rather than another cause of raised lung pressure involves testing that cannot be done remotely
• Treatment choice depends on disease classification and severity, which is assessed rather than self-reported
• Ongoing monitoring is part of the treatment, not an optional extra
• Other therapies may be combined or substituted over time as the condition changes

Why the Dosing Schedule Is Not Published Here

This page does not publish the dosing schedule, and the reason is worth stating rather than hiding.

Sildenafil tablets for erectile dysfunction can be obtained after a remote consultation. If this page printed the strength and frequency used in pulmonary arterial hypertension, it would hand anyone a recipe for approximating a specialist regimen using tablets obtainable in minutes. That is a foreseeable harm, and no amount of surrounding warning text cancels it out.

What can be said usefully is the shape of the difference, because that is what shows the two are not interchangeable.

Notice the third row. The erectile dysfunction product carries a firm instruction not to take more than one tablet a day. The pulmonary regimen involves more frequent dosing at a different strength, under supervision, for a different purpose. Those two facts sitting side by side are precisely why people should not improvise.

If you are under a specialist service, your schedule comes from them and from your dispensing label. Follow those, and raise questions with the team rather than adjusting anything yourself.

Why ED Tablets Cannot Substitute

Beyond strength and frequency, three practical points make substitution unsafe.

Consistency matters here and does not there. Treatment for pulmonary arterial hypertension is continuous, and an interruption is a clinical event rather than an inconvenience, which is why a missed dose is discussed with the treating team.

The clinical context is entirely different. Erectile dysfunction sildenafil is supplied after a questionnaire-based assessment. Pulmonary arterial hypertension involves confirmed diagnosis, disease classification, baseline measurements and structured follow-up.

The exclusions still apply, and matter more. Nitrates and nitric oxide donors remain an absolute contraindication. Riociguat, itself used in pulmonary hypertension, must never be combined with sildenafil. Someone self-treating would be doing so with nobody checking either. See our sildenafil interactions guide for the documented cautions.

Start Your Free Assessment

How Effective Is It?

Sildenafil is licensed for pulmonary arterial hypertension, which means the regulator assessed the evidence as sufficient to support that use. Being honest about what that does and does not tell you is more useful than a vague claim of effectiveness.

A licence means the regulator considered the available evidence sufficient to support the medicine's benefit-risk balance for the authorised indication. In pulmonary arterial hypertension, the endpoints used in this field typically concern exercise capacity and how the condition progresses.

What this page will not do is quote specific effectiveness figures. The verified figures we hold for sildenafil come from the erectile dysfunction studies, and transferring a number measured in one condition to another would be exactly the misattribution this page exists to avoid.

For effectiveness figures in pulmonary arterial hypertension, the specialist team is the right source, because they can also say what those numbers mean for one particular person.

Side Effects

The side effect profile follows from the mechanism, and the mechanism is the same one operating under the erectile dysfunction licence. So the familiar effects are the ones to expect.

Sildenafil can cause side effects including headache, flushing, indigestion, nausea, nasal congestion, dizziness and visual disturbances. The frequency of individual effects depends on the product, dose and population studied. Dizziness can occur and may be related to sildenafil's effects on blood pressure.

Monitoring

Monitoring in pulmonary arterial hypertension assesses the condition, the response to treatment, and any treatment-related concerns.

Sildenafil does not generally require routine drug-level monitoring. The specialist team determines which clinical assessments and investigations are appropriate as part of follow-up.

The condition is monitored regardless of which treatment is used, because it changes over time and treatment is adjusted in response. That follow-up is arranged by the specialist service and typically revisits how the condition is progressing, how well the current treatment is working, and whether anything needs to change.

Sildenafil in Specific Groups

Children

The licensed pulmonary arterial hypertension product is authorised for adults and children aged 1 to 17.

That is a genuine and important difference from the erectile dysfunction product, which is licensed only for adult men aged 18 or over and should not be given to anyone under 18. The same active substance, two different age ranges, because the licences rest on different evidence in different populations for different conditions.

Treatment in children is managed by paediatric specialist services. Dosing is weight-related and individually determined, which is a further reason no numbers appear here.

Babies and Newborns

This needs the most careful answer on the page, because the evidence points somewhere people do not expect.

The licensed age range begins at 1 year. Newborns fall outside it, and persistent pulmonary hypertension of the newborn, or PPHN, is a distinct condition from the pulmonary arterial hypertension the licence covers.

A specific safety finding belongs here. A clinical trial called STRIDER studied sildenafil given during pregnancy for intrauterine growth restriction, where a baby grows too slowly in the womb. The theory was that relaxing blood vessels might improve the blood supply reaching the baby.

The trial was stopped early. There were 17 cases of PPHN among 64 babies in the sildenafil group, including 11 deaths, against 3 cases among 58 babies on placebo. The intervention intended to help appeared to cause the very condition sildenafil is used to treat in older children.

Sildenafil is not licensed for PPHN in newborns.

Pregnancy

The pulmonary arterial hypertension product is not recommended in pregnancy unless strictly necessary, and that wording comes from MHRA advice rather than from us.

Pregnancy in pulmonary arterial hypertension is a high-risk situation in its own right, managed jointly by specialist teams. Decisions about continuing, changing or stopping treatment are made with knowledge of the individual circumstances.

The erectile dysfunction product is a separate matter entirely and is not indicated for use by women.

Anyone with pulmonary arterial hypertension who is pregnant, or planning to be, should raise it with their specialist team early rather than making any change independently.

Start Your Free Assessment

Stopping Treatment

Do not stop treatment for pulmonary arterial hypertension on your own.

The reviewed product information for the erectile dysfunction licence contains no withdrawal instruction, because a medicine taken occasionally has nothing to withdraw from. That absence does not transfer to continuous treatment for a serious condition.

In pulmonary arterial hypertension the treatment is doing continuous work. Limited data have not shown clear evidence of rebound worsening after abrupt discontinuation, but treatment changes should be supervised and may require closer monitoring.

If side effects are the reason you are considering stopping, that is a conversation with the specialist team, and one they will want to have. There may be alternatives, adjustments or supportive measures. What there is not is a good version of stopping without telling anyone.

Life Expectancy

Sildenafil's product information does not provide an individual life-expectancy estimate. Prognosis in pulmonary arterial hypertension depends on several clinical factors and should be discussed with the treating specialist.

That is not evasion, and it is worth explaining why an honest page refuses. Prognosis depends on the underlying cause, the disease classification, how far it has progressed at diagnosis, how the individual responds to treatment, other health conditions, and which combination of therapies is used. A single number quoted out of that context would mislead whichever direction it pointed.

What This Page Deliberately Does Not Cover

Being explicit about the gaps is part of being trustworthy on a subject like this.

• No dosing schedule, strength or titration
• No effectiveness figures for pulmonary arterial hypertension, because the verified figures we hold relate to a different condition
• No brand names, which serve no purpose outside a specialist service
• No prognosis or life expectancy figure
• No funding, availability or prescription cost information
• No comparison ranking against other pulmonary arterial hypertension therapies, which is a specialist decision rather than a league table

What this page does cover is the mechanism, the licence, how treatment is organised, the documented safety information, and a clear statement of where the boundary sits between the two licensed uses of the same molecule.

When to Seek Help Urgently

For anyone taking sildenafil under either licence, seek medical attention immediately for:

• Chest pain
• Fainting or collapse
• Severe or worsening breathlessness
• A sudden decrease or loss of vision, or of hearing
• An allergic reaction
• An erection lasting longer than 4 hours

If sildenafil has accidentally been taken with a nitrate or riociguat, seek prompt medical advice, because the combination can cause a significant fall in blood pressure.

Suspected side effects can be reported through the MHRA Yellow Card scheme.

Start Your Free Assessment